<DOC>
	<DOCNO>NCT02681497</DOCNO>
	<brief_summary>This study retrospective chart review study aim assess characteristic health outcome patient type 2 diabetes treat canagliflozin use addition insulin therapy . Furthermore , project aim establish EMR-based cohort patient type 2 diabetes mellitus ( T2DM ) treat canagliflozin allow future longitudinal study investigate outcomes longer follow-up period , whether canagliflozin ( use addition insulin therapy ) impact diabetes-related healthcare cost .</brief_summary>
	<brief_title>Use Canagliflozin Conjunction With Insulin Real-world Setting</brief_title>
	<detailed_description>This retrospective study use data Electronic Medical Record ( EMR ) -based database ( Web base Diabetes Records ( Web DR ) researchable database ) , use study patient 's socioeconomic characteristic , treatment pattern health outcome patient diabetes . The Web DR de-identified researchable database contains integrated demographic , clinical laboratory test result data patient receive care outpatient diabetes clinic London , Ontario . The database include 16,000 patient clinic visit information since 2000 . Adult individual ( age &gt; =18 ) type 2 diabetes receive , register Web DR treat canagliflozin conjunction insulin therapy select study . The baseline period 6 month allow complete observation comorbidities medication use pattern . The main objective project ass characteristic health outcome patient type 2 diabetes treat canagliflozin use addition insulin therapy . HbA1c , lipid , blood pressure , weight clinical indicator gather lab result baseline period close date canagliflozin prescription follow period ( last clinical value within follow-up period &gt; =30 day start medication data select . The type insulin use dosage prescribe study follow-up period extract database examine insulin dosage prescription pattern understand use insulin canagliflozin impact clinical outcome . Furthermore , use oral antihyperglycemic agent ( metformin , sulfonylurea , thiazolidinedione , alpha-glucosidase inhibitor , meglitinides , Dipeptidyl peptidase-4 ( DPP-4 ) inhibitor , bromocriptine ) injectable antihyperglycemic therapy ( pramlintide , Glucagon-like peptide-1 ( GLP-1 ) receptor agonist ) measure 6 month baseline period follow-up period 3 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Type 2DM &gt; 18 year age , diabetes patient insulin initiate Canagliflozin due need tight glycemic control . glomerular filtration rate ( GFR ) &lt; 45 , pregnancy , type 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>canagliflozin</keyword>
	<keyword>diabetes</keyword>
	<keyword>SGLT2</keyword>
	<keyword>real-world data</keyword>
</DOC>